ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc
Published 1 year ago • 472 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
2:01
ascent: sacituzumab govitecan outperforms chemo in black patients with tnbc
-
3:10
ascent trial: sacituzumab govitecan for tnbc
-
3:31
the ascent of sacituzumab govitecan in metastatic tnbc | aditya bardia
-
4:25
ascent: sacituzumab govitecan shows promise in mtnbc patients
-
2:15
ascent: sacituzumab govitecan biomarker analysis
-
0:56
pembrolizumab as adjuvant therapy for tnbc
-
2:16
efficacy of sacituzumab govitecan by trop-2 expression in patients with muc
-
1:49
final os analysis of sacituzumab govitecan in tropics-02
-
1:36
real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
-
0:41
recent advances in targeted therapies for tnbc
-
3:59
sacituzumab govitecan for treatment-refractory metastatic breast cancer
-
5:16
study of sacituzumab govitecan for triple-negative breast cancer
-
3:47
sacituzumab govitecan in mtnbc
-
0:46
oncotarget: sacituzumab govitecan in triple-negative breast cancer
-
1:47
dr. bardia on sacituzumab govitecan in tnbc
-
2:46
dr. sweeney on the phase iii enzamet trial in metastatic hormone-sensitive prostate cancer
-
2:23
dr aditya bardia discusses the advantages of sacituzumab govitecan for triple-negative breast cancer
-
2:38
trophy-u-01 cohort 3: sacituzumab govitecan pembrolizumab for patients with muc